How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
3
CRDF Quote, Financials, Valuation and Earnings
Last price:
$1.75
Seasonality move
:
-2.87%
Day range:
$1.58 - $1.76
52-week range:
$1.58 - $4.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
222.83x
P/B ratio:
2.42x
Volume:
2.2M
Avg. volume:
1.6M
1-year change:
-55.92%
Market cap:
$117.9M
Revenue:
$683K
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
$103.5K | -$0.20 | -26.61% | -8.42% | $10.25 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
INSP
Inspire Medical Systems, Inc.
|
$265.8M | $0.68 | 6.4% | -35.84% | $124.53 |
|
OM
Outset Medical, Inc.
|
$28.9M | -$0.68 | -1.68% | -79.35% | $11.75 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$16.8M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
$1.75 | $10.25 | $117.9M | -- | $0.00 | 0% | 222.83x |
|
AGEN
Agenus, Inc.
|
$2.84 | $12.33 | $96.6M | -- | $0.00 | 0% | 0.72x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
INSP
Inspire Medical Systems, Inc.
|
$78.54 | $124.53 | $2.3B | 53.87x | $0.00 | 0% | 2.67x |
|
OM
Outset Medical, Inc.
|
$5.07 | $11.75 | $90.1M | -- | $0.00 | 0% | 1.01x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$2.07 | $11.00 | $166.5M | 29.78x | $0.00 | 0% | 2.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
2.03% | 2.082 | 0.73% | 4.14x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.385 | 285.06% | 0.03x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
INSP
Inspire Medical Systems, Inc.
|
4.66% | -0.753 | 1.51% | 3.89x |
|
OM
Outset Medical, Inc.
|
40.94% | 3.743 | 38.74% | 5.74x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.674 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRDF
Cardiff Oncology, Inc.
|
-$104K | -$12M | -79.44% | -81.17% | -9978.33% | -$10.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
INSP
Inspire Medical Systems, Inc.
|
$192.7M | $9.6M | 6.32% | 6.62% | 4.3% | $58.1M |
|
OM
Outset Medical, Inc.
|
$11.6M | -$15.8M | -35.38% | -81.05% | -53.73% | -$6.5M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Cardiff Oncology, Inc. vs. Competitors
-
Which has Higher Returns CRDF or AGEN?
Agenus, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of -116.82%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About CRDF or AGEN?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 485.71%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 334.27%. Given that Cardiff Oncology, Inc. has higher upside potential than Agenus, Inc., analysts believe Cardiff Oncology, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 AGENAgenus, Inc.2 1 0 -
Is CRDF or AGEN More Risky?
Cardiff Oncology, Inc. has a beta of 1.397, which suggesting that the stock is 39.746% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.577, suggesting its more volatile than the S&P 500 by 57.698%.
-
Which is a Better Dividend Stock CRDF or AGEN?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or AGEN?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 222.83x versus 0.72x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.222.83x -- $120K -$11.3M AGENAgenus, Inc.0.72x -- $30.2M $63.9M
-
Which has Higher Returns CRDF or AIM?
AIM ImmunoTech has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of -10571.43%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About CRDF or AIM?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 485.71%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Cardiff Oncology, Inc., analysts believe AIM ImmunoTech is more attractive than Cardiff Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 AIMAIM ImmunoTech1 0 0 -
Is CRDF or AIM More Risky?
Cardiff Oncology, Inc. has a beta of 1.397, which suggesting that the stock is 39.746% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock CRDF or AIM?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or AIM?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are larger than AIM ImmunoTech quarterly revenues of $35K. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 222.83x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.222.83x -- $120K -$11.3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns CRDF or INSP?
Inspire Medical Systems, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of 4.42%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Inspire Medical Systems, Inc.'s return on equity of 6.62%.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M INSPInspire Medical Systems, Inc.85.85% $0.34 $699M -
What do Analysts Say About CRDF or INSP?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 485.71%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $124.53 which suggests that it could grow by 58.56%. Given that Cardiff Oncology, Inc. has higher upside potential than Inspire Medical Systems, Inc., analysts believe Cardiff Oncology, Inc. is more attractive than Inspire Medical Systems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 INSPInspire Medical Systems, Inc.6 8 0 -
Is CRDF or INSP More Risky?
Cardiff Oncology, Inc. has a beta of 1.397, which suggesting that the stock is 39.746% more volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.725, suggesting its less volatile than the S&P 500 by 27.474%.
-
Which is a Better Dividend Stock CRDF or INSP?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or INSP?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $224.5M. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than Inspire Medical Systems, Inc.'s net income of $9.9M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Inspire Medical Systems, Inc.'s PE ratio is 53.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 222.83x versus 2.67x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.222.83x -- $120K -$11.3M INSPInspire Medical Systems, Inc.2.67x 53.87x $224.5M $9.9M
-
Which has Higher Returns CRDF or OM?
Outset Medical, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of -60.61%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Outset Medical, Inc.'s return on equity of -81.05%.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M OMOutset Medical, Inc.39.38% -$1.00 $241M -
What do Analysts Say About CRDF or OM?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 485.71%. On the other hand Outset Medical, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 131.76%. Given that Cardiff Oncology, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Cardiff Oncology, Inc. is more attractive than Outset Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 OMOutset Medical, Inc.3 1 0 -
Is CRDF or OM More Risky?
Cardiff Oncology, Inc. has a beta of 1.397, which suggesting that the stock is 39.746% more volatile than S&P 500. In comparison Outset Medical, Inc. has a beta of 2.074, suggesting its more volatile than the S&P 500 by 107.371%.
-
Which is a Better Dividend Stock CRDF or OM?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Outset Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or OM?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Outset Medical, Inc. quarterly revenues of $29.4M. Cardiff Oncology, Inc.'s net income of -$11.3M is higher than Outset Medical, Inc.'s net income of -$17.8M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Outset Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 222.83x versus 1.01x for Outset Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.222.83x -- $120K -$11.3M OMOutset Medical, Inc.1.01x -- $29.4M -$17.8M
-
Which has Higher Returns CRDF or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -9381.67% compared to Cardiff Oncology, Inc.'s net margin of 13.19%. Cardiff Oncology, Inc.'s return on equity of -81.17% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital CRDFCardiff Oncology, Inc.-86.67% -$0.17 $49.8M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About CRDF or PLX?
Cardiff Oncology, Inc. has a consensus price target of $10.25, signalling upside risk potential of 485.71%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 431.4%. Given that Cardiff Oncology, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Cardiff Oncology, Inc. is more attractive than Protalix Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDFCardiff Oncology, Inc.7 1 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is CRDF or PLX More Risky?
Cardiff Oncology, Inc. has a beta of 1.397, which suggesting that the stock is 39.746% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.
-
Which is a Better Dividend Stock CRDF or PLX?
Cardiff Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDF or PLX?
Cardiff Oncology, Inc. quarterly revenues are $120K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Cardiff Oncology, Inc.'s net income of -$11.3M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Cardiff Oncology, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 29.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology, Inc. is 222.83x versus 2.63x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDFCardiff Oncology, Inc.222.83x -- $120K -$11.3M PLXProtalix Biotherapeutics, Inc.2.63x 29.78x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
78
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
67
PFSI alert for Jan 30
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
86
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
